Amyris (AMRS) Given a $15.00 Price Target at HC Wainwright

HC Wainwright set a $15.00 target price on Amyris (NASDAQ:AMRS) in a report released on Thursday. The firm currently has a buy rating on the biotechnology company’s stock.

Other research analysts have also recently issued research reports about the company. B. Riley set a $10.00 price objective on Amyris and gave the stock a buy rating in a research report on Monday, September 17th. BidaskClub raised Amyris from a hold rating to a buy rating in a report on Wednesday, August 15th. ValuEngine raised Amyris from a hold rating to a buy rating in a report on Thursday, June 28th. Finally, Zacks Investment Research raised Amyris from a strong sell rating to a hold rating in a report on Tuesday, July 17th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of Buy and an average price target of $9.13.

NASDAQ:AMRS opened at $8.41 on Thursday. The firm has a market capitalization of $508.54 million, a price-to-earnings ratio of -2.76 and a beta of 0.26. The company has a debt-to-equity ratio of -0.24, a current ratio of 0.42 and a quick ratio of 0.38. Amyris has a 1 year low of $2.82 and a 1 year high of $9.22.

Amyris (NASDAQ:AMRS) last released its quarterly earnings data on Monday, August 6th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.08). The business had revenue of $24.81 million during the quarter, compared to analysts’ expectations of $37.52 million. The business’s quarterly revenue was down 3.4% compared to the same quarter last year. During the same period last year, the firm earned ($1.32) EPS. As a group, sell-side analysts anticipate that Amyris will post -1.41 EPS for the current year.

In other news, COO Eduardo Alvarez bought 11,877 shares of the stock in a transaction on Wednesday, September 5th. The shares were bought at an average price of $8.45 per share, with a total value of $100,360.65. Following the completion of the acquisition, the chief operating officer now owns 331,877 shares of the company’s stock, valued at $2,804,360.65. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Kathleen Valiasek bought 14,000 shares of the stock in a transaction on Wednesday, August 22nd. The stock was purchased at an average cost of $7.20 per share, for a total transaction of $100,800.00. Following the acquisition, the chief financial officer now directly owns 228,630 shares of the company’s stock, valued at approximately $1,646,136. The disclosure for this purchase can be found here. In the last three months, insiders acquired 50,877 shares of company stock worth $393,161 and sold 8,824,625 shares worth $54,897,886. 21.80% of the stock is currently owned by corporate insiders.

Institutional investors have recently bought and sold shares of the business. Dynamic Technology Lab Private Ltd acquired a new stake in Amyris in the first quarter valued at $110,000. Fox Run Management L.L.C. acquired a new stake in shares of Amyris during the third quarter valued at $121,000. Rhumbline Advisers acquired a new stake in shares of Amyris during the second quarter valued at $147,000. Renaissance Technologies LLC acquired a new stake in shares of Amyris during the second quarter valued at $167,000. Finally, Element Capital Management LLC acquired a new stake in shares of Amyris during the first quarter valued at $227,000. 27.90% of the stock is currently owned by institutional investors.

Amyris Company Profile

Amyris, Inc provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market.

Featured Article: Exchange-Traded Funds (ETFs)

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply